Good Manufacturing Practices for Medical Devices Guidelines – Draft for Comments

China is currently revising its quality management standards for medical device production. The National Medical Products Administration (NMPA) has released a draft of the ‘Good Manufacturing Practices for Medical Devices’, which is now open for public comment till February 14, 2025.

The draft guidelines are intended to set the foundation for enhanced quality management of medical device production, establishing new requirements for risk management, production processes, and post-market surveillance.

With 15 chapters and 131 articles, this draft aims to raise the standards of medical device manufacturing in China, aligning them with global practices to ensure device safety and effectiveness throughout their lifecycle.

Overview of Good Manufacturing Practices for Medical Devices Guidelines

1) Lifecycle Risk Management

One of the key updates in the draft is a comprehensive approach to risk management. Articles 6-12 emphasize the importance of risk management throughout the lifecycle of medical devices. Manufacturers are now required to implement robust risk management systems, starting from the design phase and continuing through production, post-market surveillance, and disposal.

2) Senior Management Responsibilities

Under Articles 13-23, senior management is given clear responsibility for ensuring the implementation of quality management systems. They must allocate resources for risk assessments, provide adequate training, and maintain the infrastructure needed to meet regulatory requirements, thus ensuring ongoing compliance with the new guidelines.

3) Production and Equipment Standards

The draft also strengthens requirements related to production environments and equipment. Articles 24-34 demand that facilities adhere to stringent cleanliness and environmental control standards, and that all equipment undergoes regular validation and calibration. These requirements are designed to prevent contamination and ensure the consistency and quality of medical devices.

4) Production Process Validation

Chapters covering Articles 67-75 focus on process validation, documentation, and change control. Manufacturers will need to maintain detailed records of their production processes and demonstrate that any modifications to these processes are validated to ensure they do not compromise device quality.

Post-Market Surveillance and Compliance

Post-market surveillance is another area that has seen significant emphasis. Under Chapter 14, particularly Articles 119-127, manufacturers are required to implement post-market surveillance systems to monitor the safety and performance of medical devices after they reach the market.

This includes tracking adverse events, collecting real-world data, and acting swiftly to address any issues. Manufacturers will need to have systems in place to capture and analyze feedback from users, healthcare professionals, and regulators to ensure that devices continue to meet safety standards.

Comparison with the 2014 Guidelines

The 2025 guidelines represent a significant evolution in good manufacturing practices for medical devices, emphasizing comprehensive lifecycle management, risk-based approaches, and enhanced quality assurance mechanisms. These updates reflect global trends towards more rigorous oversight and adaptability to technological advancements.

While the 2014 guidelines served as a solid foundation, the 2025 version ensures greater alignment with international best practices, addressing gaps in traceability, personnel accountability, and post-market surveillance.

Category2025 Draft Guidelines2014 GuidelinesCommentsPurpose and ScopeExpanded to include life cycle activities, e.g., design, development, sales.Focused primarily on production and quality management.The 2025 guidelines adopt a broader lifecycle perspective, enhancing traceability and accountability.Risk ManagementEmphasizes risk management throughout the entire lifecycle.Risk management applied mainly during production stages.Reflects a shift towards proactive risk mitigation across all phases of product realization.Documentation and RecordsStipulates more detailed document control and record retention policies.General guidance on record-keeping requirements.Enhances traceability and aligns with international best practices.Design and DevelopmentIncludes specific stages like design input, verification, and validation.Limited references to design control.The 2025 guidelines recognize the importance of rigorous design and development controls.Product TraceabilityIntroduces requirements for unique device identification (UDI).Does not reference UDI.Aligns 2025 standards with global regulatory trends for device identification.Post-Market SurveillanceAdds structured requirements for adverse event monitoring and reporting.Limited to basic customer feedback handling.Strengthens the focus on product safety after market release.Outsourcing and CommissioningImposes stricter controls and evaluation of outsourcing partners.Provides broad requirements for outsourced activities.Enhances confidence in the quality of outsourced processes in 2025.Software ValidationRequires validation for software impacting production and quality.No explicit requirement for software validation.Reflects recognition of the role of software in modern manufacturing and quality control.Recall and Risk MitigationEstablishes detailed recall and corrective action processes.Mentions recalls without detailing procedures.The 2025 version offers a comprehensive framework for handling defective or unsafe products.

Implications for Foreign Medical Device Manufacturers

For foreign medical device manufacturers looking to enter or expand in the Chinese market, the new guidelines present both challenges and opportunities. Companies will need to ensure that their quality management systems meet the updated requirements, particularly around lifecycle risk management and post-market surveillance.

The new regulations will also require a careful review of existing processes, documentation, and facilities to ensure compliance. Manufacturers should be prepared to implement stronger controls over production processes, validate their equipment regularly, and take greater responsibility for monitoring device performance once on the market.

How to Submit Comments on the Draft Guidelines

The draft is now open for public comment, and feedback is welcome from relevant organizations and individuals. Those wishing to contribute their suggestions or concerns must submit them to mdgmp@cfdi.org.cn by February 14, 2025.When submitting, please indicate "Good Manufacturing Practices for Medical Devices – Feedback and Suggestions" in the subject line of the email.

Final Thoughts

China’s revised Good Manufacturing Practices for Medical Devices guidelines are a crucial step in aligning the country’s regulatory framework with international standards. For manufacturers, this is an opportunity to prepare for an increasingly competitive market by enhancing their compliance with the highest quality management standards.

By participating in the public comment process and adjusting their quality systems, manufacturers can ensure they remain well-positioned to succeed in China’s rapidly growing medical device market.

Further Information

Read in full the original NMPA draft of the Good Manufacturing Practices for Medical Devices.

To learn how these new guidelines might impact your organization, please contact the Cisema team.